Is the standard childhood vaccination schedule safe and effective — what does the evidence say about timing and spacing?

The question

Is the standard childhood vaccination schedule safe and effective — and what does the evidence say about timing and spacing? In other words: should you follow the recommended timetable, or is there a safer way to delay, separate, or spread out your child's vaccines?

Short answer

Yes. Across large studies and national surveillance data, the vaccines on the standard schedule are highly effective at preventing serious disease, and serious side effects are rare [1,29]. There is no evidence that delaying or spreading out vaccines makes them safer — the main measurable effect of delay is a longer window in which your child is unprotected [2,3]. For some vaccines, vaccinating late is actually linked to a slightly higher risk of side effects: delaying the first MMR past 15 months roughly doubles the small risk of a fever-related seizure, and delaying the first rotavirus dose past 3 months more than triples its small intussusception risk [4,5].

What the strongest evidence says

The vaccines work — and the diseases they prevent are not mild

Two doses of the measles-containing vaccine are about 97% effective at preventing measles (one dose about 93%) [6]. Globally, measles vaccination is estimated to have averted around 57 million deaths between 2000 and 2022 [7]. The disease itself is far from harmless: in developed settings, measles causes pneumonia in roughly 50–60 of every 1,000 cases, brain inflammation (encephalitis) in about 1–2 per 1,000, death in about 1–3 per 1,000, and a rare fatal brain disorder (SSPE) in an estimated 0.2–0.7 per 1,000 cases, with higher risk when infection happens in very young children [8].

Before Hib vaccination, about 1 in 200 children under five — 5 in every 1,000 — developed invasive Hib disease, mostly meningitis; after conjugate Hib vaccines were introduced, incidence fell by 99% [9]. Of children who got Hib meningitis, around 4% died and 15–30% of survivors were left with hearing loss or lasting neurological problems [9]. For whooping cough (pertussis), about one in three infected infants under one year needs hospital care, and 84% of recorded pertussis deaths between 2000 and 2017 were in babies under two months old — too young to be fully vaccinated [10]. Three doses of pertussis vaccine are about 88% effective [11], and in a large US surveillance study of infant pertussis cases, babies who had received at least one DTaP dose from six weeks of age were substantially less likely to die than unvaccinated babies [12].

The schedule as a whole has been reviewed — and no safety signal found

In 2013, the US Institute of Medicine (now the National Academy of Medicine) carried out a consensus review of the entire childhood schedule. It found no evidence that the recommended schedule is unsafe, and no schedule-level link to autoimmune disease, asthma, allergies, seizures, or developmental, learning, or attention disorders [1]. But the review was candid about a limitation: evidence evaluating the whole schedule as one exposure was thin, because randomly assigning babies to a deliberately delayed or unvaccinated schedule would be unethical [1]. That gap is permanent — we will never have that trial — so schedule-level safety rests on large observational datasets such as the Vaccine Safety Datalink rather than randomized experiments.

MMR, autism, and thimerosal: the most-studied questions in vaccine safety

The claim that MMR causes autism has been tested in some of the largest vaccine studies ever run. A Danish cohort of 537,303 children found the relative risk of autistic disorder in vaccinated versus unvaccinated children was 0.92 — essentially no difference [13]. A later, larger Danish cohort of 657,461 children found an adjusted hazard ratio of 0.93, with no increased risk even in children considered more susceptible [14]. A US study of 95,727 children found no link even among children with an older sibling with autism — the highest-risk group [15]. A 2014 meta-analysis pooling over 1.2 million children found no association between MMR and autism (odds ratio 0.84) or between thimerosal/mercury exposure and autism (odds ratios 1.00) [16].

The thimerosal (mercury-based preservative) hypothesis was tested separately: in Denmark, autism rates kept rising after thimerosal was removed from vaccines in 1992 — the opposite of what the hypothesis predicts [17]. A US cohort of 1,047 children given 42 detailed neuropsychological tests at ages 7–10 found no pattern of harm linked to early thimerosal exposure [18]. Thimerosal was removed from routine childhood vaccines years ago as a precaution, even though the studies did not support a link [17].

Delaying has not been shown to reduce side effects — and it extends the unprotected window

A US study of 1,047 children found that getting vaccines on time in the first year was not linked to worse neuropsychological outcomes at ages 7–10 on any of 42 tests — and on-time children scored slightly better on several measures [19]. In other words, there is no measured developmental benefit to waiting.

What delay clearly does is leave children exposed. In a case-control study of 72 pertussis cases, 47% of the sick children had fallen behind the DTaP schedule, compared with 22% of healthy controls — and the further behind, the higher the risk. Because this design compares sick and healthy children rather than following one group over time, it can't give the absolute risk for any single child [2]. A separate cohort study of 323,247 children found nearly half had been undervaccinated at some point, and 2.8% were on identifiable alternative schedules — of those, only about 1 in 10 were fully caught up by age two [3]. (One nuance worth stating honestly: a later cohort study of 316,404 children found that persistent undervaccination raised pertussis risk about fivefold, while brief delays among children who ultimately got all their doses were not clearly linked to higher risk — but no study found delay reduced harm [20].)

For some vaccines, later is measurably riskier

MMR and febrile seizures. A study of 323,247 children found no link between the timing of infant vaccines and seizures in the first year — but in the second year it mattered. A first MMR dose at 12–15 months carried a seizure risk of about 1 in 4,000 doses; delaying it to 16–23 months roughly doubled that to about 1 in 2,000 [4]. These febrile seizures are brief and frightening but do not cause epilepsy or lasting harm [21].

MMRV vs separate shots. The combined MMRV vaccine (measles, mumps, rubella plus chickenpox) caused about 4.3 extra febrile seizures per 10,000 doses — roughly 1 extra seizure per 2,300 doses — in the week after vaccination compared with giving MMR and chickenpox vaccines separately on the same day [22]. At the second dose (ages 4–6), no extra risk was found [23]. This is a genuine, small exception to the general rule that combination vaccines are as safe as separate ones. Note for UK parents: since January 2026 the UK schedule gives MMRV as the first dose at 12 months [24], so this small risk applies to the current UK programme — at roughly 1 extra seizure per 2,000–2,500 doses, against the protection the vaccine provides.

Rotavirus and intussusception. Rotavirus vaccines carry a small risk of intussusception (a bowel blockage), concentrated in the week after early doses. A meta-analysis of ten studies found 1.7 extra cases per 100,000 vaccinated children when the first dose is given at the recommended age — but 5.6 extra cases per 100,000 when the first dose is given after three months of age [5]. Because the background risk of intussusception rises as babies get older, vaccinating on time is actually safer in absolute terms than delaying. A US benefit–risk model estimated vaccination averts about 1,093 hospitalisations for every intussusception hospitalisation it might cause [25].

"Too many, too soon"? What immunology says

A 2002 review of infant immunology concluded that multiple simultaneous vaccines do not overwhelm or "use up" the immune system [26]. (Its much-quoted "capacity for 10,000 vaccines" figure is a theoretical illustration, not a tested safety threshold — treat it as an argument about scale, not a clinical finding [26].) On aluminium adjuvants — a common worry — a pharmacokinetic model estimated first-year vaccine aluminium exposure stays below conservative safety thresholds [27], and a 2026 paediatric review put current first-year exposure at roughly 2–3.4 mg while acknowledging the evidence is modelling-based, not from randomized outcome trials [28]. This is worth knowing, but it is a secondary issue: no study links the schedule's aluminium content to clinical harm.

Serious allergic reactions are extremely rare

Across 25 million vaccine doses, confirmed vaccine-triggered anaphylaxis occurred at a rate of 1.31 per million doses — about 1 in 760,000 doses — with no deaths and no vaccine-attributed cases in children under four [29]. Most affected people had a history of allergies or asthma [29].

What it means for the parents (not just the child)

Most of the evidence above is about your child — but the schedule lands on you too, in a few measurable ways.

Your child's vaccines protect the household a little, not just your child. When the rotavirus vaccine was introduced for US babies, hospitalisations fell in unvaccinated older children and adults as well — an estimated 10,000 hospitalisations averted in 2008 among people aged five and up [30]. In Chicago, rotavirus found in adults with diarrhoea roughly halved after children started being vaccinated [31]. A careful household study of the flu vaccine (part of the schedule from age two) found that vaccinating a child roughly halved the chance of passing flu to an unvaccinated adult at home — but because most flu is caught out in the community, the adult's overall infection risk fell only about 5% [32]. The honest summary: your child's vaccines give the rest of the household — including you — some extra protection. They don't make you immune.

Sick children cost parents working days. This is best measured for flu rather than the infant schedule. In one US study following schoolchildren through a flu season, for every 100 children, parents missed about 20 extra days of work and families saw about 22 secondary illnesses [33] — though this was two schools in one city, so treat it as an illustration rather than a national figure. Put together: preventing illness in your child probably saves you sick days too — but no study has measured that directly for the standard infant schedule, so treat it as a reasonable inference, not a proven number. (Parental-outcomes evidence rating: C.)

The practical bit. The schedule as written means a fixed set of appointments. Spreading vaccines out means more of them — more time off work, more waiting rooms, and more weeks with less protection.

If this decision feels heavy, you're not alone. In one US survey, parents who delayed or refused vaccines were about eight times more likely to say they were constantly re-evaluating their decision [34]. For many parents, the questioning doesn't stop once you decide — whichever way you decide.

What remains uncertain

• There is no randomized trial of the whole standard schedule versus a delayed schedule, and there never will be — it would be unethical. Schedule-level safety evidence is therefore observational [1].
• Long-term follow-up of children raised on alternative schedules is sparse; most delay evidence is observational and tangled with the reasons families delay [3].
• Aluminium safety rests on pharmacokinetic modelling plus surveillance, not randomized outcome trials; preterm infants are understudied [28].
• How large the "non-specific" effects of vaccines are (for example, measles' temporary weakening of immune memory) remains an active research question [8].

Benefits and risks in absolute terms

All figures per 1,000 children unless stated.

Practical considerations

• What the schedule looks like (UK, from January 2026): at 8, 12, and 16 weeks, the 6-in-1 vaccine plus MenB (with rotavirus drops at 8 and 12 weeks and pneumococcal at 16 weeks); at 12 months, pneumococcal, MenB, and MMRV; at 18 months, a 6-in-1 and MMRV booster for children born from July 2024 onwards; at 3 years 4 months, the 4-in-1 pre-school booster; HPV at 12–13 and a teenage booster at 14 [24]. Schedules differ by country — the evidence above covers the vaccines, not one country's exact timetable.
• If you fall behind, catch-up is what matters: contact your GP surgery rather than restarting or inventing your own spacing [24].
• Spreading vaccines out means more appointments, more time off, more waiting-room exposures — and every week of delay is a week with less protection, against diseases that hit hardest in the first months of life [3,10].
• Combination vaccines generally mean fewer injections without less protection. If your child has had a febrile seizure before, mention it to your clinician — they may discuss timing and which combination to use. In the UK the routine first dose at 12 months is the combined MMRV [22,24].

When to talk to your doctor, midwife, or pediatrician

• Your child had a severe allergic reaction to a previous vaccine dose.
• Your child has an immune system disorder, or takes medicines that suppress immunity.
• Your child had a seizure after a previous vaccination — the clinician may adjust which combination is used and when.
• You are considering delaying or skipping any vaccine: ask about catch-up options and the specific diseases your child would be exposed to in the meantime.
• You have read something alarming about a vaccine ingredient and want to talk it through — bring the source if you can.

References

1. Institute of Medicine. The Childhood Immunization Schedule and Safety: Stakeholder Concerns, Scientific Evidence, and Future Studies. Washington, DC: National Academies Press; 2013. Free full text: https://www.ncbi.nlm.nih.gov/books/NBK206948/ — [B]
2. Glanz JM, et al. Association between undervaccination with diphtheria, tetanus toxoids, and acellular pertussis (DTaP) vaccine and risk of pertussis infection in children 3 to 36 months of age. JAMA Pediatr. 2013;167(11):1060-1064. doi:10.1001/jamapediatrics.2013.2353 — [B]
3. Glanz JM, et al. A population-based cohort study of undervaccination in 8 managed care organizations across the United States. JAMA Pediatr. 2013;167(3):274-281. https://jamanetwork.com/journals/jamapediatrics/fullarticle/1558057 — [B]
4. Hambidge SJ, et al. Timely versus delayed early childhood vaccination and seizures. Pediatrics. 2014;133(6):e1492-e1499. doi:10.1542/peds.2013-3429 — [B]
5. Koch J, Harder T, von Kries R, Wichmann O. Risk of intussusception after rotavirus vaccination: a systematic literature review and meta-analysis. Dtsch Arztebl Int. 2017;114:255-262. doi:10.3238/arztebl.2017.0255 — [B]
6. Centers for Disease Control and Prevention. Measles vaccination: how well does the measles vaccine work? Two doses ~97% effective; one dose ~93%. https://www.cdc.gov/measles/vaccination.html — [B]
7. Minta AA, et al. Progress toward measles elimination — worldwide, 2000–2022. MMWR. 2023. Estimated 57 million measles deaths averted by vaccination, 2000–2022 (modelled). https://pmc.ncbi.nlm.nih.gov/articles/PMC10684353/ — [C]
8. Measles complications in developed settings: pneumonia ~50–60/1,000; encephalitis ~1–2/1,000; death ~1–3/1,000 (https://pubmed.ncbi.nlm.nih.gov/38422396/); SSPE ~0.2–0.7/1,000, higher after very early infection (https://publications.aap.org/aapnews/news/11910/Measles-associated-with-numerous-complications); measles "immune amnesia" (http://cdc.gov/measles/about/questions.html) — [B]
9. Centers for Disease Control and Prevention. Haemophilus influenzae invasive disease: ~1 in 200 children under five developed invasive Hib disease pre-vaccine; meningitis in ~two-thirds of invasive cases, ~4% fatal, 15–30% of meningitis survivors with lasting sequelae; incidence fell 99% after conjugate vaccines. https://www.cdc.gov/surv-manual/php/table-of-contents/chapter-2-haemophilus-influenzae.html; http://cdc.gov/mmwr/preview/mmwrhtml/rr6301a1.htm — [B]
10. Centers for Disease Control and Prevention. Pink Book, Pertussis chapter: ~1 in 3 infants under one year with pertussis hospitalised; 84% of 2000–2017 deaths in infants under 2 months. https://www.cdc.gov/pinkbook/hcp/table-of-contents/chapter-16-pertussis.html — [B]
11. Centers for Disease Control and Prevention. Pertussis, United States 1997–2000: 3-dose VE 88% (95% CI 79–93%) in children 7–18 months. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5104a1.htm — [B]
12. Tiwari TSP, et al. Pediatrics. 2015 (doi:10.1542/peds.2014-2291): infants ≥42 days with ≥1 DTaP dose 72% less likely to die from pertussis (aOR 0.28). Reported at https://www.mdedge.com/familymedicine/article/99374/pediatrics/pertussis-vaccination-infants-reduces-death-hospitalization — [B]
13. Madsen KM, et al. A population-based study of measles, mumps, and rubella vaccination and autism. N Engl J Med. 2002;347(19):1477-1482. doi:10.1056/NEJMoa021134 — [B]
14. Hviid A, et al. Measles, mumps, rubella vaccination and autism: a nationwide cohort study. Ann Intern Med. 2019;170(8):513-520. doi:10.7326/M18-2101 — [B]
15. Jain A, et al. Autism occurrence by MMR vaccine status among US children with older siblings with and without autism. JAMA. 2015;313(15):1534-1540. doi:10.1001/jama.2015.3077 — [B]
16. Taylor LE, Swerdfeger AL, Eslick GD. Vaccines are not associated with autism: an evidence-based meta-analysis of case-control and cohort studies. Vaccine. 2014;32(29):3623-3629. doi:10.1016/j.vaccine.2014.04.085 — [B]
17. Madsen KM, et al. Thimerosal and the occurrence of autism: negative ecological evidence from Danish population-based data. Pediatrics. 2003;112(3 Pt 1):604-606. doi:10.1542/peds.112.3.604 — [C]
18. Thompson WW, et al. Early thimerosal exposure and neuropsychological outcomes at 7 to 10 years. N Engl J Med. 2007;357(13):1281-1292. doi:10.1056/NEJMoa071434 — [B]
19. Smith MJ, Woods CR. On-time vaccine receipt in the first year does not adversely affect neuropsychological outcomes. Pediatrics. 2010;125(6):1134-1141. doi:10.1542/peds.2009-2489 — [B]
20. Rane M, Rohani P, Halloran ME. Association of diphtheria-tetanus–acellular pertussis vaccine timeliness and number of doses with age-specific pertussis risk in infants and young children. JAMA Netw Open. 2021;4(8):e2119118. doi:10.1001/jamanetworkopen.2021.19118. https://doi.org/10.1001/jamanetworkopen.2021.19118 — [B]
21. Centers for Disease Control and Prevention. MMR vaccine and febrile seizures: ~1 additional seizure per 3,000–4,000 vaccinated children; by age 5, ~1 in 25 children has had a febrile seizure (peak 14–18 months), usually without lasting effects. http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5903a1.htm — [B]
22. Klein NP, et al. Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures. Pediatrics. 2010;126(1):e1-e8. doi:10.1542/peds.2010-0665 — [B]
23. Klein NP, et al. Measles-containing vaccines and febrile seizures in children age 4 to 6 years. Pediatrics. 2012;129(5):809-814. doi:10.1542/peds.2011-3198 — [B]
24. UK Health Security Agency. Complete routine immunisation schedule from 1 January 2026. https://www.gov.uk/government/publications/the-complete-routine-immunisation-schedule/complete-routine-immunisation-schedule-from-1-january-2026 — [guidance]
25. Desai R, et al. Potential intussusception risk versus benefits of rotavirus vaccination in the United States. Pediatr Infect Dis J. 2013 (PMID 22929172). https://pmc.ncbi.nlm.nih.gov/articles/PMC5714269/ — [C]
26. Offit PA, et al. Addressing parents' concerns: do multiple vaccines overwhelm or weaken the infant's immune system? Pediatrics. 2002;109(1):124-129. doi:10.1542/peds.109.1.124. Note: the "10,000 vaccines" figure is a theoretical illustration, not a tested threshold. https://publications.aap.org/pediatrics/article/109/1/124/79755/Addressing-Parents-Concerns-Do-Multiple-Vaccines — [C]
27. Mitkus RJ, et al. Updated aluminum pharmacokinetics following infant exposures through diet and vaccination. Vaccine. 2011;29(51):9538-9543. Pharmacokinetic model; absorption assumptions debated. — [C]
28. American Academy of Pediatrics. The role and safety of aluminum adjuvants in childhood vaccines (clinical report). Pediatrics. 2026;157(3):e2025074874. https://pmc.ncbi.nlm.nih.gov/articles/PMC13366423/ — [B]
29. McNeil MM, et al. Risk of anaphylaxis after vaccination in children and adults. J Allergy Clin Immunol. 2016;137(3):868-878. 33 confirmed cases after 25,173,965 doses: 1.31 per million; no deaths; none vaccine-attributed in children under 4. https://divisionofresearch.kaiserpermanente.org/publications/risk-of-anaphylaxis-after-vaccination-in-children-and-adults/ — [B]
30. Lopman BA, et al. Infant rotavirus vaccination may provide indirect protection to older children and adults in the United States. J Infect Dis. 2011;204(7):980–986. Ecological before-after: ~10,000 hospitalisations averted in 2008 among unvaccinated people aged 5+. doi: 10.1093/infdis/jir492 — [C]
31. Anderson EJ, et al. Rotavirus in adults requiring hospitalization. Clin Infect Dis. 2013;56(6):755–760. Rotavirus detection in Chicago adults with diarrhoea roughly halved after paediatric vaccine introduction. doi: 10.1093/cid/cis1010 — [C]
32. Tsang TK, et al. Transmissibility of influenza in a household study during the 2009–2010 influenza B epidemic in Hong Kong. Nat Commun. 2019;10:106. Cluster household RCT (796 households): vaccinating a child roughly halved household transmission to an unvaccinated adult (relative probability 0.69 one child, 0.55 all children); adult total infection risk fell only ~5%. doi: 10.1038/s41467-018-08036-6 — [B]
33. Neuzil KM, et al. Burden of interpandemic influenza in children younger than 5 years: a 25-year prospective study. Arch Pediatr Adolesc Med. 2002;156(10):986–991. Seattle school study: ~20 extra parental workdays missed and ~22 secondary family illnesses per 100 children per flu season. doi: 10.1001/archpedi.156.10.986 — [C]
34. Glanz JM, et al. Acad Pediatr. 2013;13(5):456–463. 7 focus groups + survey (n=443, 52% response, Kaiser Permanente Colorado): parents who delayed/refused were ~8x more likely to constantly re-evaluate their vaccination decision. PMID 24011751 — [C]

Changelog

• 2026-09-07: Topic created (draft). Evidence rating B (provisional, pending independent review).
• 2026-09-08: Parental-outcomes audit applied: added "What it means for the parents" section (flu workday/income evidence, school-programme natural experiment, routine-schedule evidence gap, appointment burden); added refs 30–36. Topic rating unchanged (B).
• 2026-09-09: Full review (Guille via delegated agent review). Rating confirmed B. Changes: replaced secondary CIDRAP link for the IOM/National Academies 2013 schedule review with the primary NCBI Bookshelf full text; replaced the secondary Contemporary Pediatrics report on pertussis undervaccination with the primary Rane 2021 JAMA Network Open cohort; reframed three relative-risk-only passages to absolute/qualitative language (Glanz 2013 DTaP case-control now 47% vs 22% with case-control caveat; removed the confounded 21% inpatient-admission claim; Tiwari 2015 pertussis-mortality now qualitative); narrowed the Hib table row to schedule-level wording; cut the Nettleman 2001 survey and King 2006 non-randomised school-flu claims from the parents section (refs 34–35 removed, old ref 36 renumbered to 34); softened the MMRV separate-shots advice for the UK 2026 programme; toned down "across hundreds of studies". Hambidge 2014 absolute framing ("about 1 in 4,000 → 1 in 2,000") verified as the study author's own quoted framing, consistent with published IRRs. Status: approved.